Want to see SHTDY full AI Analyst Report?
SHTDY Stock Chart & Stats
$13.13
-$0.11(-0.80%)
At close: 4:00 PM EST
$13.13
-$0.11(-0.80%)
Day’s Range― - ―
52-Week Range$9.94 - $14.04
Previous CloseN/A
Volume2.10K
Average Volume (3M)1.38K
Market Cap
$6.99B
Enterprise Value$92.34B
Total Cash (Recent Filing)$61.60B
Total Debt (Recent Filing)$108.65B
Price to Earnings (P/E)6.6
Beta0.16
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.53%
Share Statistics
EPS (TTM)11.35
Shares Outstanding268,362,150
10 Day Avg. Volume773
30 Day Avg. Volume1,375
Financial Highlights & Ratios
PEG Ratio-4.41
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market Cap13.20
Enterprise Value/Revenue0.16
Enterprise Value/Gross Profit2.23
Enterprise Value/Ebitda4.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extensive Distribution NetworkA broad national logistics and sales footprint is a durable competitive advantage for a pharmaceutical distributor. Scale and reliable fulfillment lower per-unit costs, improve supplier access and contract wins, and support stable order flow from hospitals and pharmacies over the medium term.
Consistent Cash GenerationStrong cash conversion indicates earnings translate into real cash, supporting operational stability, dividends and working-capital needs. Even with recent declines, consistent FCF coverage of net income provides financial flexibility versus peers with weaker cash conversion.
Diversified Revenue StreamsA mix of wholesale distribution, device/diagnostic sales and retail pharmacies reduces reliance on any single segment or tender channel. Diversification supports margin mix management and offers multiple growth levers (retail expansion, value‑added logistics) that persist over months.
Bears Say
Weakening Revenue And MarginsDeclining top-line and compressed margins indicate structural pressure on pricing and product mix. Reduced operating leverage limits reinvestment into logistics and retail expansion, weakens ability to absorb costs, and will pressure profitability and ROE over the coming months.
Rising LeverageA meaningful step-up in leverage reduces financial flexibility in a low-margin distribution business. Higher debt increases interest burden and constrains capital allocation choices (capex, M&A, buybacks), making the company more vulnerable to cash flow volatility and regulatory shifts.
Declining Free Cash Flow TrendA sharp drop in free cash flow limits capacity to sustain dividends, invest in network upgrades or pay down debt. Even if FCF historically covered earnings, a continuing downward trend could force tradeoffs among capex, working capital and deleveraging, weakening resilience.
Sinopharm Group Co News
SHTDY FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
Sinopharm Group Co lowest stock price was $9.94 and its highest was $14.04 in the past 12 months.
What is Sinopharm Group Co’s market cap?
Sinopharm Group Co’s market cap is $6.99B.
When is Sinopharm Group Co’s upcoming earnings report date?
Sinopharm Group Co’s upcoming earnings report date is Aug 31, 2026 which is in 41 days.
How were Sinopharm Group Co’s earnings last quarter?
Currently, no data Available
Is Sinopharm Group Co overvalued?
According to Wall Street analysts Sinopharm Group Co’s price is currently Overvalued.
Does Sinopharm Group Co pay dividends?
Sinopharm Group Co pays a Annually dividend of $0.509 which represents an annual dividend yield of 4.53%. See more information on Sinopharm Group Co dividends here
What is Sinopharm Group Co’s EPS estimate?
Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Group Co have?
Sinopharm Group Co has 268,362,150 shares outstanding.
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sinopharm Group Co?
Currently, no hedge funds are holding shares in SHTDY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinopharm Group Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.49%
12-Months-Change
Fundamentals
Return on Equity
4.53%
Trailing 12-Months
Asset Growth
3.79%
Trailing 12-Months
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharmaceutical Distribution segment is responsible for supplying a wide array of pharmaceutical products to various healthcare entities, including hospitals, clinics, and retail pharmacies. This segment also provides comprehensive logistics and value-added services to both domestic and international manufacturers and suppliers of pharmaceutical and healthcare items. The Medical Devices segment focuses specifically on the distribution of medical equipment. Through its Retail Pharmacy segment, the company operates and franchises an extensive chain of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment encompasses the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core activities, Sinopharm Group also engages in property rental and management, distributes specialized products such as Chinese herbal medicines, antibiotics, and biological products, and offers a suite of services. These include IT development, medicine, business, health, and market information consulting, international trade (import/export of goods and technology), market investigation, and convention and exhibition services. Furthermore, the company is involved in medical project investment, consulting, and technology training. To enhance its commercial capabilities and transformation, Sinopharm Group Co. Ltd. maintains a strategic partnership with I-Mab. Founded in 2003, the company is headquartered in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.